Monthly Archives: August 2016

Home – Minnesota Regenerative Medicine

Posted: August 18, 2016 at 4:49 am

The specialty of regenerative medicine at Minnesota Regenerative Medicine focuses on the bodys natural ability to repair, replace, and regenerate damaged or aging tissues, and to restore functionality.

Using stem cell therapy, a patient can tap into their bodys ability to regenerate and heal itself by using the healthy regenerative cells found throughout the body. The stem cell treatment offerings available at Minnesota Regenerative Medicine make it possible to harvest these regenerative cells from a patients adipose tissue, then inject them back into the patient at sites of degeneration and injury to restore and repair aging or damaged cells to effectively regenerate tissue in the body. Stem cell therapy allows patients with painful osteoarthritic joints and chronic tendinitis to receive non-surgical orthopedic care on an outpatient basis without being exposed to the dangers inherent with general anesthesia and orthopedic surgery.

The specific type of stem cell treatments being offered at Minnesota Regenerative Medicine is designed for patients with joint or tendon pain due to osteoarthritis or chronic tendinitis involving the knee, shoulder, hip, ankle/foot, wrist/hand, elbow and Achilles tendon.

While stem cell treatments have been used for decades to treat a variety of diseases, stem cell therapy in orthopedic and sports medicine is relatively new. This treatment is for suitable candidates only and presently is not a covered benefit of Medicare or private insurance. At Minnesota Regenerative Medicine, stem cell treatment is neither a research study, nor clinical study.

More here:
Home - Minnesota Regenerative Medicine

Posted in Minnesota Stem Cells | Comments Off on Home – Minnesota Regenerative Medicine

Human Induced Pluripotent Stem Cell Derived Neuronal Cells …

Posted: August 18, 2016 at 4:49 am

Bal-Price, A. et al. International STakeholder NETwork (ISTNET): creating a developmental neurotoxicity (DNT) testing road map for regulatory purposes. Arch. Toxicol. 89, 269287 (2015).

Crofton, K. M. et al. Developmental neurotoxicity testing: Recommendations for developing alternative methods for the screening and prioritization of chemicals. ALTEX-Altern. Anim. Exp. 28, 915 (2011).

Grandjean, P. & Landrigan, P. J. Neurobehavioural effects of developmental toxicity. Lancet Neurol. 13, 330338 (2014).

Bellinger, D. C. A Strategy for Comparing the Contributions of Environmental Chemicals and Other Risk Factors to Neurodevelopment of Children. Environ. Health Perspect. 120, 501507 (2012).

Olson, H. et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regulatory Toxicology and Pharmacology 32, 5667 (2000).

National Research Council Toxicity Testing in the 21st Century: A Vision and a Strategy. (The National Academies Press, Washington, DC, 2007).

Judson, R. et al. In vitro and modelling approaches to risk assessment from the U.S. Environmental Protection Agency ToxCast programme. Basic Clin. Pharmacol. Toxicol. 115, 6976 (2014).

Pellett, S. in Botulinum Neurotoxins. Vol. 364. (eds. A. Rummel & T. Binz) 257285 (Springer-Verlag Berlin, Berlin, 2013).

Whitemarsh, R. C. M., Tepp, W. H., Johnson, E. A. & Pellett, S. Persistence of Botulinum Neurotoxin A Subtypes 15 in Primary Rat Spinal Cord Cells. PLoS One 9, e90252 (2014).

Whitemarsh, R. C. M. et al. Characterization of Botulinum Neurotoxin A Subtypes 1 Through 5 by Investigation of Activities in Mice, in Neuronal Cell Cultures, and In Vitro. Infect. Immun. 81, 38943902 (2013).

Whitemarsh, R. C. M. et al. Novel Application of Human Neurons Derived from Induced Pluripotent Stem Cells for Highly Sensitive Botulinum Neurotoxin Detection. Toxicol. Sci. 126, 426435 (2012).

McNutt, P., Celver, J., Hamilton, T. & Mesngon, M. Embryonic stem cell-derived neurons are a novel, highly sensitive tissue culture platform for botulinum research. Biochem. Biophys. Res. Commun. 405, 8590 (2011).

Kiris, E. et al. Embryonic stem cell-derived motoneurons provide a highly sensitive cell culture model for botulinum neurotoxin studies, with implications for high-throughput drug discovery. Stem Cell Research 6, 195205 (2011).

Nuss, J. E. et al. Development of Cell-Based Assays to Measure Botulinum Neurotoxin Serotype A Activity Using Cleavage-Sensitive Antibodies. J. Biomol. Screen 15, 4251 (2010).

Lee, J.-O., Rosenfield, J., Tzipori, S. & Park, J.-B. M17 human neuroblastoma cell as a cell model for investigation of Botulinum Neurotoxin A activity and evaluation of BoNT/A specific antibody. The Botulinum Journal 1, 135152 (2008).

Pellett, S., Tepp, W. H., Clancy, C. M., Borodic, G. E. & Johnson, E. A. A neuronal cell-based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies. FEBS Lett. 581, 48034808 (2007).

Fernandez-Salas, E. et al. Botulinum Neurotoxin Serotype a Specific Cell-Based Potency Assay to Replace the Mouse Bioassay. PLoS One 7 (2012).

Pantano, S. & Montecucco, C. The blockade of the neurotransmitter release apparatus by botulinum neurotoxins. Cell. Mol. Life Sci. 71, 793811 (2014).

Gill, D. M. Bacterial toxins - A table of lethal amounts. Microbiological Reviews 46, 8694 (1982).

Pirazzini, M. et al. Thioredoxin and Its Reductase Are Present on Synaptic Vesicles, and Their Inhibition Prevents the Paralysis Induced by Botulinum Neurotoxins. Cell Reports 8, 18701878 (2014).

Montal, M. In Annual Review of Biochemistry, Vol 79, (eds. R.D. Kornberg, C. R. H. Raetz, J. E. Rothman & J. W. Thorner) 591617 (Annual Reviews, Palo Alto, 2010).

Fischer, A. et al. Bimodal modulation of the botulinum neurotoxin protein-conducting channel. Proc. Natl. Acad. Sci. USA 106, 13301335 (2009).

Fischer, A. & Montal, M. Crucial role of the disulfide bridge between botulinum neurotoxin light and heavy chains in protease translocation across membranes. J. Biol. Chem. 282, 2960429611 (2007).

Schiavo, G., Matteoli, M. & Montecucco, C. Neurotoxins affecting neuroexocytosis. Physiol. Rev. 80, 717766 (2000).

Schiavo, G., Rossetto, O., Tonello, F. & Montecucco, C. Intracellular targets and metalloprotease activity of tetanus and botulism neurotoxins. Curr. Top. Microbiol. Immunol. 195, 257274 (1995).

Montecucco, C. & Schiavo, G. Mechanism of action of tetanus and botulinum neurotoxins. Mol. Microbiol. 13, 18 (1994).

Hoyle, C. E. & Bowman, C. N. Thiol-Ene Click Chemistry. Angew. Chem. -Int. Edit. 49, 15401573 (2010).

Fairbanks, B. D. et al. A versatile synthetic extracellular matrix mimic via thiol-norbornene photopolymerization. Adv. Mater. 21, 50055010 (2009).

Hansen, T. D. et al. Biomaterial arrays with defined adhesion ligand densities and matrix stiffness identify distinct phenotypes for tumorigenic and non-tumorigenic human mesenchymal cell types. Biomaterials Science 2, 745756 (2014).

Lin, C.-C., Ki, C. S. & Shih, H. Thiolnorbornene photoclick hydrogels for tissue engineering applications. J. Appl. Polym. Sci. In Press (2015).

Van Hove, A. H., Beltejar, M.-J. G. & Benoit, D. S. W. Development and in vitro assessment of enzymatically-responsive poly(ethylene glycol) hydrogels for the delivery of therapeutic peptides. Biomaterials 35, 97199730 (2014).

Wang, C., Tong, X. M. & Yang, F. Bioengineered 3D Brain Tumor Model To Elucidate the Effects of Matrix Stiffness on Glioblastoma Cell Behavior Using PEG-Based Hydrogels. Mol. Pharm. 11, 21152125 (2014).

Nguyen, E. H., Zanotelli, M. R., Schwartz, M. P. & Murphy, W. L. Differential effects of cell adhesion, modulus and VEGFR-2 inhibition on capillary network formation in synthetic hydrogel arrays. Biomaterials 35, 21492161 (2014).

Musah, S. et al. Substratum-induced differentiation of human pluripotent stem cells reveals the coactivator YAP is a potent regulator of neuronal specification. Proceedings of the National Academy of Sciences 111, 1380513810 (2014).

Hynes, W. F. et al. Micropatterning of 3D Microenvironments for Living Biosensor Applications. Biosensors 4, 2844 (2014).

McKinnon, D. D., Kloxin, A. M. & Anseth, K. S. Synthetic hydrogel platform for three-dimensional culture of embryonic stem cell-derived motor neurons. Biomaterials Science 1, 460469 (2013).

Schwartz, M. P. et al. A Quantitative Comparison of Human HT-1080 Fibrosarcoma Cells and Primary Human Dermal Fibroblasts Identifies a 3D Migration Mechanism with Properties Unique to the Transformed Phenotype. PLoS One 8, e81689 (2013).

Gramlich, W. M., Kim, I. L. & Burdick, J. A. Synthesis and orthogonal photopatterning of hyaluronic acid hydrogels with thiol-norbornene chemistry. Biomaterials 34, 98039811 (2013).

Lin, C.-C., Raza, A. & Shih, H. PEG hydrogels formed by thiol-ene photo-click chemistry and their effect on the formation and recovery of insulin-secreting cell spheroids. Biomaterials 32, 96859695 (2011).

Anderson, S. B., Lin, C. C., Kuntzler, D. V. & Anseth, K. S. The performance of human mesenchymal stem cells encapsulated in cell-degradable polymer-peptide hydrogels. Biomaterials 32, 35643574 (2011).

Benton, J. A., Fairbanks, B. D. & Anseth, K. S. Characterization of valvular interstitial cell function in three dimensional matrix metalloproteinase degradable PEG hydrogels. Biomaterials 30, 65936603 (2009).

Yu, J. Y. et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 318, 19171920 (2007).

Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861872 (2007).

Thomson, J. A. et al. Embryonic stem cell lines derived from human blastocysts. Science 282, 11451147 (1998).

Zhang, S. C., Wernig, M., Duncan, I. D., Brustle, O. & Thomson, J. A. In vitro differentiation of transplantable neural precursors from human embryonic stem cells. Nat. Biotechnol. 19, 11291133 (2001).

Liu, H. S. & Zhang, S. C. Specification of neuronal and glial subtypes from human pluripotent stem cells. Cell. Mol. Life Sci. 68, 39954008 (2011).

Gaspard, N. & Vanderhaeghen, P. Mechanisms of neural specification from embryonic stem cells. Curr. Opin. Neurobiol. 20, 3743 (2010).

Eiraku, M. & Sasai, Y. Self-formation of layered neural structures in three-dimensional culture of ES cells. Curr. Opin. Neurobiol. 22, 768777 (2012).

Xu, X. H. & Zhong, Z. Disease modeling and drug screening for neurological diseases using human induced pluripotent stem cells. Acta Pharmacol. Sin. 34, 755764 (2013).

Hou, Z. et al. A human pluripotent stem cell platform for assessing developmental neural toxicity screening. Stem Cell Res. Ther. 4 (Suppl 1), S12 (2013).

Schantz, E. J. & Johnson, E. A. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiological Reviews 56, 8099 (1992).

Pierschbacher, M. D. & Ruoslahti, E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 309, 3033 (1984).

Hatheway, C. in Laboratory Diagnosis of Infectious Diseases. (eds. A. Balows, W. J. Hausler, Jr., M. Ohashi, A. Turano & E. H. Lennete) 111133 (Springer New York, 1988).

Schantz, E. J. & Kautter, D. A. Standardized Assay for Clostridium-Botulinum Toxins. Journal of the Association of Official Analytical Chemists 61, 9699 (1978).

Hughes, C. S., Radan, L., Betts, D., Postovit, L. M. & Lajoie, G. A. Proteomic analysis of extracellular matrices used in stem cell culture. Proteomics 11, 39833991 (2011).

Li, X. J. et al. Directed differentiation of ventral spinal progenitors and motor neurons from human embryonic stem cells by small molecules. Stem Cells 26, 886893 (2008).

Nagase, H. & Fields, G. B. Human matrix metalloproteinase specificity studies using collagen sequence-based synthetic peptides. Biopolymers 40, 399416 (1996).

Sarnat, H. B., Nochlin, D. & Born, D. E. Neuronal nuclear antigen (NeuN): a marker of neuronal maturation in the early human fetal nervous system1. Brain and Development 20, 8894 (1998).

Lampe, K. J., Mooney, R. G., Bjugstad, K. B. & Mahoney, M. J. Effect of macromer weight percent on neural cell growth in 2D and 3D nondegradable PEG hydrogel culture. J. Biomed. Mater. Res. Part A 94A, 11621171 (2010).

Saha, K. et al. Substrate Modulus Directs Neural Stem Cell Behavior. Biophys. J. 95, 44264438 (2008).

Leipzig, N. D. & Shoichet, M. S. The effect of substrate stiffness on adult neural stem cell behavior. Biomaterials 30, 68676878 (2009).

Cox, T. R. & Erler, J. T. Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. Dis. Model. Mech. 4, 165178 (2011).

Miyake, K., Satomi, N. & Sasaki, S. Elastic modulus of polystyrene film from near surface to bulk measured by nanoindentation using atomic force microscopy. Appl. Phys. Lett. 89, 031925 (2006).

Rakic, P. Developmental and evolutionary adaptations of cortical radial glia. Cereb. Cortex 13, 541549 (2003).

Ader, M. & Tanaka, E. M. Modeling human development in 3D culture. Curr. Opin. Cell Biol. 31, 2328 (2014).

Malizio, C., Goodnough, M. & Johnson, E. in Bacterial Toxins: Methods and Protocols. Vol. 145. (ed. O. Holst) 2739 (Humana Press, 2000).

Pellett, S., Tepp, W. H., Toth, S. I. & Johnson, E. A. Comparison of the primary rat spinal cord cell (RSC) assay and the mouse bioassay for botulinum neurotoxin type A potency determination. J. Pharmacol. Toxicol. Methods 61, 304310 (2010).

Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to Image J: 25 years of image analysis. Nat Meth 9, 671675 (2012).

Rasband, W. S. (Image J, U.S. National Institutes of Health, Bethesda, Maryland, USA, http://imagej.nih.gov/ij/ 1997-2012).

See the rest here:
Human Induced Pluripotent Stem Cell Derived Neuronal Cells ...

Posted in Maryland Stem Cells | Comments Off on Human Induced Pluripotent Stem Cell Derived Neuronal Cells …

Diabetes Australia

Posted: August 18, 2016 at 4:45 am

New PBS listing will improve quality of life for people with type 2 diabetes 15 August 2016

Diabetes Australia welcomed the Minister for Health Sussan Leys announcement of the Federal Governments decision to list diabetes drug Bydureon on the Pharmaceutical Benefits Scheme (PBS) and said the move would improve quality of life for many people with type 2 diabetes.

Aged 18 - 35 and living with type 1 diabetes? You can help with a survey into Online Youth Empowerment and Support.The survey aims to find out the usefulness and effectiveness of an online diabetes service on diabetes self-management during life transitions in young adults with type 1 diabetes.

Albert Abdul- Rahman has had a lifetime of adapting to change which stands him in good stead to face one of the biggest challenges in his life: learning to walk again after his left foot was amputated just three weeks ago.

Aged 19, Albert left Papua New Guinea for Queensland where he joined the Australian army: "There was no way I was prepared for the culture shock, I thought I knew about life in Australia, but everything was different to what I was used to." Albert embraced life with the army and spent six years as an engineer, learning a great deal about his new country and remaining an important part of the Papua New Guinea community living in Townsville.

Diabetes Australia and OPSM have partnered to raise awareness of diabetes and eye health in Australia. Each day 280 Australians develop diabetes thats one every five minutes.

From Kim Kardashian to Russell Crowe, masseur to the stars Philip Rule was comfortable dealing with the biggest names in sport and entertainment.

He was on top of the world work-wise and feeling healthy so a diagnosis of type 2 diabetes came out of the blue for 5th generation coalminer who, as well as being a massage whiz, has 30 years experience underground.

I was diagnosed with type 2 diabetes in 2005. I wasnt particularly overweight and I didnt think I was unhealthy so it was a bit of a surprise, Philip said.

Truck driver Jake Williams from Flemington in Melbourne was diagnosed with Type 1 diabetes at 11 years old. Once he and his family got over the initial shock of diagnosis, Jake got into a routine of dealing with his diabetes and throughout his teens gave as little thought as possible to managing his health.

Busy with work and the responsibilities of being a new dad, diabetes was definitely on the back burner during his twenties; I really didnt let my diabetes have much effect on my life. When you have a young family and youre busy with work, its easy to miss appointments and ignore any little warning signs

Read the original here:
Diabetes Australia

Posted in Diabetes | Comments Off on Diabetes Australia

Diabetes Prevention and Control – New Jersey

Posted: August 17, 2016 at 10:43 am

Diabetes is an important health concern particularly if you are a person with diabetes or at high risk for developing it; have loved one with diabetes; or are a health care provider or public health practitioner. Diabetes is serious, common and costly, yet it is controllable. The New Jersey Diabetes Prevention and Control Program seeks to reduce the health impacts of diabetes by:

Diabetes Disaster Guidelines [pdf 211kb]

Grant Programs

Commission for the Blind & Visually Impaired/Diabetic Eye Disease Detection Program

NJ 2-1-1 Diabetes Education and Prevention Program Services The NJ Department of Health has partnered with NJ 2-1-1, to provide the most up-to-date information on diabetes prevention and education to New Jersey residents.

NJ 2-1-1 is a statewide non-emergency, information call center and website. NJ 2-1-1 call specialists will provide callers with information on local Diabetes Prevention Programs and Diabetes Self-Management Education programs. Please feel free to visit the website, http://nj211.org/diabetes-management-and-prevention, to learn more about this partnership.

See the rest here:
Diabetes Prevention and Control - New Jersey

Posted in Diabetes | Comments Off on Diabetes Prevention and Control – New Jersey

NJDOH – Family Health services – New Jersey

Posted: August 17, 2016 at 10:43 am

Behavioral Risk Factor Surveillance System (BRFSS) data for 2003-2005 estimate that 473,000 adults 18 years and older, 7.2 % (margin of sampling error .3%) of the population, have been diagnosed with diabetes. It is estimated that 190,000 individuals have diabetes but have not been diagnosed.

For a variety of reasons, it is anticipated that the trend of increasing numbers and rates of people with diabetes will continue unless measures are taken that are geared toward prevention. Among people at the highest risk are persons over the age of 45, persons who are obese, and minorities. New Jersey 's population is aging. The number of persons over the age of 45 went from 2,594,232 in 1990 to an estimated 3,340,127 in 2005. Obesity rates, as estimated by BRFSS, went from 10% in 1991 to 22.1% in 2005. The state has always been diverse and is becoming more so. The percentage of black-non-Hispanics in New Jersey went from 12.7% in 1990 to 13.3% in 2005; while the percentage of the population that is Hispanic went from 9.6% to 14.5%. The Asian population had the fastest rate of growth increasing from 3% to 7.3% of the total population in 2005. The fastest growing subgroup among Asians is Asian-Indians. That group increased from 79,440 in 1990 to 169,180 in 2000.

According to the BRFSS for the period of 2003-2005, the highest rate by age of diagnosed diabetes was for persons 65 and over. For that group, the rate was 16.7% (margin of sampling error .9) compared to 7.2% (margin of error.3) for all persons over age 18. The survey shows blacks have the highest rate by race/ethnicity. The rate among non- Hispanic blacks of all ages was 12.2% (margin of sampling error 1.3).

Go here to see the original:
NJDOH - Family Health services - New Jersey

Posted in Diabetes | Comments Off on NJDOH – Family Health services – New Jersey

Regenerative Stem Cell Injections | Stem Cell Therapy Illinois

Posted: August 14, 2016 at 1:49 am

About R3 and Illinois Pain Network

R3 Stem Cell offers regenerative treatment options throughout the US that bring patients hope along with relief. Hope that surgery may be avoided, and regeneration and repair of damaged tissue without surgery. The person may then be able to participate in desired activities like swimming, biking, hiking, football, golf, playing with your kids again and being Pain Free!

R3 Stem Cell partners with the top pain and orthopedic practices nationwide to offer stem cell and PRP therapy to those desiring state-of-the-art treatment by compassionate, Board Certified providers. The Illinois Pain Network offers the top pain management providers in Chicago, Rockford, Joliet, Peoria, Naperville and surrouding areas. R3 is proud to work with the professionals in the Network, helping patients to receive regenerative therapies with the latest effective technology available.

Conventional pain treatments have been very good at reducing pain by masking discomfort in a band aid fashion with oral or injected medications like steroids, narcotics, or NSAIDs. These therapies unfortunately do not fix the underlying problem.

Fixing Tissue Injury

So how is the condition actually repaired, whether its shoulder/knee/hip/ankle arthritis, back or neck pain, golfers or tennis elbow, rotator cuff tendonitis or a ligament injury?

Regenerative Medicine with the Illinois Pain Network has the potential to restore anatomy with stem cells, growth factors and platelets to facilitate a healing response in ones own body.

Stem Cells are like a blank slate and may differentiate into any number of cell types for tissue regeneration. This is in large part dependent on the environment in which they are placed.

Illinois Stem Cell Procedures

Stem cell injection treatments include:

These are all minimally invasive, same day, low risk, outpatient procedures. The treatments may be partially covered by insurance.

Initial studies are showing these stem cell therapies to offer substantial promise in healing injury while reducing pain. For example, most professional sports leagues have approved of PRP therapy along with the World Anti-Doping Association.

Pro athletes who have received regenerative medicine treatment include the likes of Rafael Nadal, Dwight Howard, Tiger Woods, Kobe Bryant, Bartolo Colon and many more.

All of the treatments with the Illinois Pain Network are performed by Board Certified physicians.

Dr. Mark Farag is a double-board certified and fellowship-trained anesthesiologist and interventional pain management specialist. He attended the University of Illinois at Chicago for his anesthesiology residency and interventional pain management fellowship.

He is compassionate, intelligent, and always dedicated to giving his patients the highest quality of care. He focuses on using a multi-modal approach (procedures, medications, physical therapy, and other therapies) to treat the pain at its source, and help his patients resume a fulfilling personal, professional, and social life.

Dr. Rakic is double-board certified in both anesthesiology and pain management. He was a professor at the University of Illinois, specializing in in general anesthesia, regional anesthesia and pain management. He is interested in spine and orthopedic pain, cancer pain, as well as neuropathic pain conditions.

He brings a University level of care to patients and loves to offer regenerative medicine procedures including PRP and stem cell therapy to help provide relief. Most patients are able to avoid surgery and increase their functional abilities. Dr. Rakic also speaks Spanish and Serbian.

Dr. Pontinen is a double-board certified anesthesiologist and interventional pain medicine specialist. He has also undergone formal training as a resident in general surgery, which allows him to perform the most innovative procedures in pain medicine safely and skillfully.

He is a compassionate physician who works daily to help his patients regain their lives and get back to doing the activities they love. He is passionate about treating the most complex pain cases in a comprehensive, integrative and holistic approach, combining multiple treatment modalities with the most innovative, minimally invasive procedures.

This includes cutting edge regenerative medicine procedures for arthritis, tendonitis, sports injuries, migraines, chronic wounds and more.

Dr. Saldanha is double-board certified in both anesthesiology and pain medicine. Dr. Saldanha is a compassionate physician who is driven to provide healthcare to patients, regardless of background.

His expertise spans both medical management and interventional procedures, which includes PRP and stem cell therapy. Patients with all types of bone, joint and soft tissue conditions are treated with the regenerative medicine procedures to help repair and regenerate injury!

If you would like to receive stem cell therapy partially covered by insurance, CONTACT US or call (888) 885-8675 today!

Save

Save

Save

Here is the original post:
Regenerative Stem Cell Injections | Stem Cell Therapy Illinois

Posted in Illinois Stem Cells | Comments Off on Regenerative Stem Cell Injections | Stem Cell Therapy Illinois

Regenexx injections – Stem Cells – The KNEEguru

Posted: August 14, 2016 at 1:48 am

Advertisement

Advertisement

Does anyone know anything about the newly patented injections of Regenexx. It says it is a mixture of bone marrow stem cells (taken from your hip) and blood from your vein. This mixture is then injected into your knee. Clinical trials have resulted in ~ 30% cartilage regrowth. Not bad.

Left knee - 1997 debridement, 1999 trochlea paste graft / microfracture), 2002 IAGH injections, 2005 plica and synovium removal, 2009 Regenexx injections Right knee - 1997 debridement, 2000 trochlea paste graft, 2004 IAGH injections, 2008 Regenexx injections

I have been wondering the same thing.. Sounds great if it works? Has anyone on this list heard or had any involvement with the folks in Colorado?

I'm a little supicious of that. I want to ask my knee doc about it.

I wish we can find someone who tried it.

I am hoping to get the permission of my health insurance to be evaluated by him to see if I am a suitable candidate. Anything that will postpone the TKR for as long as possible.

http://www.alphaklinik.de/en/toft/news/Stem_Cell_therapy

Sue in Germany

1989 big trauma R. knee - sorted 1990-2004 3ACL recons and 20+ arthroscopies -RK 3/06 LK ACL torn! 4/06 ACL recon, kneecap broken 09 &10/06- 2x meniscus trims 3/07 - Notch Plastic & Lateral Release 14/8/08 complete revision ACL plus LCL/PLC recon 6/2/09 returned to skiing! Whoopee

How many injectons did you have and how long did it take to feel better? Did you have any restrictions.

Thanks

Left knee - 1997 debridement, 1999 trochlea paste graft / microfracture), 2002 IAGH injections, 2005 plica and synovium removal, 2009 Regenexx injections Right knee - 1997 debridement, 2000 trochlea paste graft, 2004 IAGH injections, 2008 Regenexx injections

I filled out the online form and got a response back within a few hours. I have emailed back & forth with them several times. They are supposed to open an office in Fla. soon.

TKR finally done!!! 9/9/13 Whew!!

In response to your email, Dr. Centeno and his associates are having good success in treating patients with OA/DJD of the knees as well as degenerative disk disease, with loss of cartilage, with our non surgical procedure. The best method for them to give you their feedback to whether you could benefit from Regenexx is to review your most recent MRIs or x-rays. If you would be interested, we would be happy to do this.

Our website http://www.regenexx.com has the most updated information regarding the procedure along with Dr. Centenos latest publications. Regenexx is currently only available at our Denver location although we plan to open in Florida later in the year. The procedure involves drawing our patients blood and bone marrow, growing their stem cells in our laboratory for approximately 3 weeks and then injecting the stem cells into the affected joint. Patients come to Denver for an overnight stay for their blood and bone marrow draw and then for up to 9 days for a series of injections to place the stem cells. This timeframe is dependent on the course of therapy prescribed to address your particular issues.

Please let me know what additional questions you may have or how I may assist you.

Thank you for your interest.

All the best!

Kelly Fulton, RN Regenerative Sciences Unleash the power of your stem cells

TKR finally done!!! 9/9/13 Whew!!

http://www.pittsburghlive.com/x/pittsburghtrib/s_578202.html

There are overachievers, and then there is Dr. Joe Maroon.

Three or four days a week, he swims an hour at Sewickley YMCA, beginning at 5:15 a.m., before heading to his job as vice chairman of the department of neurological surgery at University of Pittsburgh Medical Center. He'll operate, see patients or both, and then he'll bike or jog for about an hour.

Every weekend, Maroon does his own version of a triathlon, swimming one to two miles, biking 50 to 75 miles and running between eight and 15 miles in one day. Last weekend, it was a 1.5-mile swim, 75-mile ride and 12-mile run.

"The problem is I have to double that for Hawaii," Maroon said.

Maroon, who is the Steelers' neurosurgeon, is in training for the Ford Ironman World Championship in Kona, Hawaii, this October.

The race consists of a 2.4-mile open-ocean swim, 112 miles of biking and 26.2 miles of running.

Maroon is 67 years old and will be 68 at the time of the race.

A year ago, Maroon's colleagues were telling him his racing career was over.

The trouble started five years ago, when the Sewickley resident was competing in his fifth Ironman race and injured his left knee. He continued to race, but his last major competition was in 2005, when he finished in sixth place in his age group in the triathlon at the Senior Olympics, held in Pittsburgh.

Last year, Maroon was told by two orthopedic surgeons that he was going to need a knee replacement.

That was unacceptable.

"They told me if I had an artificial knee, I'd never run again," Maroon said. "I could walk, but I'd never run again."

Maroon started researching on the Internet and found Dr. Christopher Centeno and his Colorado-based company, Regenerative Services. Centeno developed a procedure called Regenexx, in which he extracts stem cells from a patient's own bone marrow, cultivates them, then injects them into the affected area to regenerate bone and cartilage.

Eight months ago, Maroon got the first of two injections into his left knee, and last weekend he completed a half-Ironman distance race in Muncie, Ind. He finished fifth in his age group and qualified for the Ironman World Championship in the process.

The procedure, which costs $5,000 to $7,000, is not covered by insurance. Maroon knows of no one in the Pittsburgh area doing similar work.

Centeno said that while his typical patient is active and between 40 and 60 years old, Maroon will be the first to go on to compete in an Ironman.

"I kid Joe that I think he's the biggest overachiever that I know," Centeno said. "We're thankful he did well."

This will be Maroon's third trip to Kona.

"I started 20 years ago doing triathlons," he said. "Each year I just increased the bar, just like I do with my training now. That's the remarkable thing about it; you see what your body can do and adjust to."

Karen Price can be reached at [emailprotected] or 412-320-7980. Back to headlines

TKR finally done!!! 9/9/13 Whew!!

I have to tell you though, I am mightily impressed that one of their success stories is the vice chairman of the Pittsburg neurological surgery dept. Not too shabby.

This product is considered a new drug because it is used to treat human disease. There are testimonials to that right on his website. As such, the product is subject to FDA regulation, but Dr. Centeno has not gone through the proper procedures to get FDA approval. He has not filed an Investigational New Drug Application, nor has he gotten an approved Biologics License. Do we even know if there have been any clinical trials conducted? Without these, how are we to know about any potential side effects and how often they may occur?

FDA regulations were put into place to safeguard the public against false claims or untested and potentially harmful medicines. I am highly suspicious of anyone who isn't willing to go through the proper channels to get his/her product approved. It can be a long, drawn out process that takes years to complete, but the fact that it is so thorough means that in the end, you can be sure of having a product that is truly effective without being harmful. As much as I would like to believe in this product, I would urge everyone considering it to use extreme caution.

There is one other consideration also. If the product doesn't get FDA approval, insurance companies will never cover the procedure and patients will continue to have to pay out of pocket for it. Anyone considering the treatment should ask the company whether they will still be charged if the harvested cells fail to grow in the lab. My OS has stated that that sometimes happens with cells grown for ACI, but patients are still responsible for the full fee.

Here is the link to the FDA letter, if anyone wants to read it: http://www.fda.gov/CBER/compl/regen072508.htm Terre

RK 7/04 part. m. menisc., plica resect., MF 3/05 part. m. menisc., open OATS 1/07 part l. menisc., MF, patellar chondroplasty 9/08 MF LK 11/04 & 8/06 part m. menisc. 7/07 LR, patellar tendon debrid., part m. menisc.

TKR finally done!!! 9/9/13 Whew!!

The rest is here:
Regenexx injections - Stem Cells - The KNEEguru

Posted in Hawaii Stem Cells | Comments Off on Regenexx injections – Stem Cells – The KNEEguru

Bridgewater, New Jersey – American Diabetes Association

Posted: August 14, 2016 at 1:44 am

72

Share:

New Jerseyans are increasingly feeling the effects of diabetes as thousands of people suffer from the disease, and many others may have diabetes and not know it! It is estimated that one out of every three children born after 2000 in the United States will be directly affected by diabetes.

That is why the American Diabetes Association's New Jersey office is so committed to educating the public about how to stop diabetes and support those living with the disease.

We are here to help.

Additional Events

The American Diabetes Association's New Jersey office provides great local programs for people living with diabetes, their friends and family. Learn about our available programs.

The following New Jersey businesses and organizations have been designated Health Champions from the American Diabetes Association. This designation recognizes organizations that inspire and encourage organizational well-being and is part of the Association's Wellness Lives Here initiative. Learn more.

BD Horizon Blue Cross Blue Shield of New Jersey JBL Electric Nestle Nutrition Quest Diagnostics Verizon

Sign upfor our monthly newsletter to learn about news and events in the New Jersey area.

If you would like a representative from the American Diabetes Association to speak at your event or if you would like materials to distribute at a health fair or expo, please call 732-469-7979. You can also email your request tobmarsicano@diabetes.org.

We welcome your help.

Your involvement as an American Diabetes Association volunteer whether on a local or national level will help us expand our community outreach and impact, inspire healthy living, intensify our advocacy efforts, raise critical dollars to fund our mission, and uphold our reputation as the moving force and trusted leader in the diabetes community.

Find volunteer opportunities in our area through the Volunteer Center.

Here is the original post:
Bridgewater, New Jersey - American Diabetes Association

Posted in Diabetes | Comments Off on Bridgewater, New Jersey – American Diabetes Association

Maryland Stem Cell Center Consortium and Core Facility …

Posted: August 12, 2016 at 4:48 pm

In order to take advantage of the potential of stem cells for the purposes of regenerative medicine, robust standardized methods are required to generate sufficient quantities of stem cells that meet defined criteria for specific stem/progenitor cell populations.

Currently, the availability of these cells for research, drug screening and therapeutic use is limited due to technical challenges associated with their generation and expansion. On May 3, 2011, The University of Maryland School of Medicines Center for Stem Cell Biology and Regenerative Medicine and Paragon Bioservices, Inc., a contract research and GMP manufacturing company, received a Biotechnology Shared Resource Award from the state of Maryland to establish The Maryland Stem Cell Consortium to facilitate the research, commercial development and clinical application of stem cell based technologies and therapies. A key component of the consortium is the establishment of a stem cell core facility that has expertise to expand and differentiate induced pluripotent stem cells, mesenchymal stem cells, and other types of stem cells for laboratory and clinical research under GLP/GMP conditions, as needed. This core facility is open to all, without intellectual property reach-through. Cell banking and genetic modification of stem cells is also available. The core services are available on a fee-for-service model that is open to the wider stem cell community, public and private, especially in the state of Maryland. Life Technologies, Inc., a global biotechnology company that is a provider of scientific products and reagents, is also participating in the consortium and providing training opportunities for research scientists.

As a founding member of the consortium, the University of Maryland School of Medicine Center for Stem Cell Biology & Regenerative Medicine is committed to developing strong interactions between academia and the private sector and seeks to facilitate the partnering of faculty expertise with that of the external private and public sectors. The Center faculty are interested in the analysis of molecular pathways regulating basic stem cell biology, characterization of stem and progenitor cell properties to improve expansion of stem cells for transplantation, optimization of directed differentiation of pluripotent cells into distinct cell lineages, functional characterization of differentiated cells and testing the translational potential of stem cell and their progeny. Taking advantage of patient material from the University of Maryland Hospital System (a network of 12 hospitals centered at the adjacent ~1000-bed University of Maryland Medical Center plus the Baltimore Veterans Administration Hospital), Center faculty are establishing induced pluripotent stem models for human disease, such as Gauchers Disease. The Centers researchers are also using mesenchymal stem cells for repair of a range of tissue types; and several of our cardiologists and cardiac surgeons are involved in clinical trials to test stem cell-mediated cardiac repair. Via the Maryland Stem Cell Consortium, we hope to encourage productive scientific and intellectual interactions between researchers in academia, government and private sectors to accelerate stem cell related discoveries and their translation into much-needed treatments.

If you would like more information about the Maryland Stem Cell Consortium or are interested in participating, please contact the Center.

Continue reading here:
Maryland Stem Cell Center Consortium and Core Facility ...

Posted in Maryland Stem Cells | Comments Off on Maryland Stem Cell Center Consortium and Core Facility …

About Stem Cell Therapy in Scottsdale, Phoenix, AZ

Posted: August 12, 2016 at 4:45 pm

Home About Stem Cell Therapy

The Scottsdale Stem Cell Treatment Center provides stem cell therapy for residents of Scottsdale, Phoenix and the surrounding Arizona communities.

Stem-cell therapy is an intervention strategy that introduces new adult stem cells into damaged tissue in order to treat disease or injury. Many medical researchers believe that stem-cell treatments have the potential to change the face of human disease and alleviate suffering. The ability of stem cells to self-renew and give rise to subsequent generations with variable degrees of differentiation capacities offers significant potential for generation of tissues that can potentially replace diseased and damaged areas in the body, with minimal risk of rejection and side effects.

This section will discuss:

And ask the question:

The Cell Surgical Network and its affiliate treatment centers are not offering stem cell therapy as a cure for any condition, disease, or injury. No statements or implied treatments on this website have been evaluated or approved by the FDA. This website contains no medical advice. All statements and opinions provided by this website are provided for educational and informational purposes only and we do not diagnose or treat via this website or via telephone. The Cell Surgical Network and its affiliate treatment centers are offering patient funded research to provide individual patients with Stromal Vascular Fraction that contains their own autologous stem cells and growth factors and the treatment centers provide surgical procedures only and are not involved in the use or manufacture of any investigational drugs.

The Cell Surgical network does not claim that any applications, or potential applications, using autologous stem cells are approved by the FDA, or are even effective. We do not claim that these treatments work for any listed nor unlisted condition, intended or implied. Its important for potential patients to do their own research based on the options that we present so that one can make an informed decision. Any decision to participate in our patient funded experimental protocols is completely voluntary.

ATTENTION: If you have ANY concern with stromal vascular fraction, any of our products, methods, website, or technique and think we may be violating any U.S. law, pleasecontact usso that we can investigate the matter or concern immediately.

The Scottsdale Stem Cell Treatment Center provides cutting-edge care for patients in Scottsdale, Phoenix and the surrounding Arizona communities with a wide variety of degenerative disorders using adult stem cell regenerative therapy.

Marvin Borsand, D.O., F.A.C.O.S, F.A.A.C.S. is focused on providing you with the most innovative techniques and advanced procedures for harvesting and deploying adult stem cells from your own fat.

Read more:
About Stem Cell Therapy in Scottsdale, Phoenix, AZ

Posted in Arizona Stem Cells | Comments Off on About Stem Cell Therapy in Scottsdale, Phoenix, AZ